Angelman syndrome

What Angelman syndrome is

Angelman syndrome — first described by Harry Angelman in 1965 — is a rare neurogenetic disorder affecting how the nervous system develops. Children have severe developmental delay and very limited or absent spoken language, although understanding is usually better than speech.

A distinctive, happy and sociable manner with frequent laughter and excitability is characteristic, alongside an unsteady (ataxic), sometimes jerky gait, hyperactivity and a short attention span. Most children also have epilepsy, a recognisable EEG pattern, and disrupted sleep.

The genetic cause (UBE3A and imprinting)

Angelman syndrome is caused by loss of function of UBE3A — but only the copy inherited from the mother matters in the brain. Because of a process called genomic imprinting, neurons normally use the maternal UBE3A copy and switch off the paternal copy. When the maternal copy is missing or faulty, neurons are left with no working UBE3A.

There are four main mechanisms: a deletion of the 15q11–q13 region on the maternal chromosome (about 70% of cases), a pathogenic variant within the maternal UBE3A gene, paternal uniparental disomy (two paternal copies of chromosome 15), and an imprinting defect. Identifying which mechanism is present is important — both for genetic counselling and, increasingly, for eligibility for the new therapies.

Crucially for treatment, the paternal UBE3A copy is fully intact but kept silent in neurons by a natural 'antisense' transcript (UBE3A-ATS). Most of the emerging therapies work by switching this silent paternal copy back on.

How it presents

• Severe developmental delay, usually evident in the first year or two of life
• Little or no spoken language, with relatively better comprehension and use of gestures or communication aids
• Unsteady, ataxic and sometimes jerky movements; balance difficulties
• A happy, excitable manner with frequent laughter and smiling
• Hyperactivity, short attention span, and often a fascination with water
• Feeding difficulties in infancy and disrupted sleep are common

Epilepsy and sleep

Epilepsy affects roughly 80–90% of children, usually starting between 1 and 3 years of age (about a quarter before the first birthday). The most common seizure types are myoclonic and atypical absence seizures. Fever-provoked seizures and prolonged non-convulsive status epilepticus are recognised, sometimes subtle, features that are important to identify.

Broad-spectrum medicines such as valproate, clobazam, levetiracetam, ethosuximide, lamotrigine and topiramate are commonly used, and the ketogenic or low-glycaemic diet and vagus nerve stimulation are options in difficult cases. Some narrow-spectrum sodium-channel medicines (for example carbamazepine, oxcarbazepine and vigabatrin) are generally avoided because they can worsen generalised seizures. Melatonin is widely used to help the sleep difficulties that are so common in Angelman syndrome.

Current management

There is no causal treatment yet, so care is supportive and multidisciplinary, aiming to maximise development, communication and quality of life. This typically combines physiotherapy, occupational therapy, speech and language therapy with augmentative and alternative communication (AAC), behavioural support and special education, together with management of seizures and sleep.

Because the condition affects so many areas at once, coordinated input across disciplines — and clear information for the family — makes a real difference.

The genetic pipeline: therapies to reactivate UBE3A

The most promising emerging treatments aim to 'switch on' the intact but silent paternal UBE3A copy in neurons, by blocking the UBE3A-ATS transcript that normally keeps it off. Several antisense oligonucleotide (ASO) therapies — given by injection into the spinal fluid — have now reached late-stage trials. All remain investigational and are not yet approved.

• GTX-102 (apazunersen, Ultragenyx) — an intrathecal ASO targeting UBE3A-AS. Its global Phase 3 Aspire study (children aged 4–17 with a full maternal UBE3A deletion) completed enrolment, with results expected in the second half of 2026; an additional study (Aurora) is extending it to other genotypes and ages. It holds FDA Breakthrough Therapy and Fast Track designations.
• ION582 (Ionis) — an ASO that showed clinically meaningful improvements for most participants in its Phase 1/2 HALOS study; the pivotal Phase 3 REVEAL study, which includes both children and adults with a UBE3A deletion or variant, is underway. It also holds FDA Breakthrough Therapy designation.
• Rugonersen (RO7248824) — Roche stopped its own development after early data fell short, but global rights were acquired by Oak Hill Bio, which plans a new Phase 3 programme from 2026.
• Earlier-stage (preclinical or early-clinical) approaches include CRISPR-based activation and zinc-finger transcription factors to unsilence paternal UBE3A, and small molecules targeting downstream pathways.

How an educational review can help

An Angelman diagnosis raises many questions at once — what the specific genetic result means, how seizures and sleep are best supported, which therapies and supports to prioritise, and whether a clinical trial might one day be relevant. An educational review can explain the genetic and EEG findings in plain language, set out how the current plan fits established guidance, and help you prepare focused questions for your treating team.

It is an educational second opinion — not a diagnosis, treatment or prescription — and it does not replace the care of your child's own clinicians.